Bimagrumab
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Completed · Enrollment 507
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo/30 mg/kg Bimagrumab | Obesity or overweight | 30 mg | 4 | n/r | n/r |
| 10/30 mg/kg Bimagrumab | Obesity or overweight | 30 mg | 4 | n/r | n/r |
| 30 mg/kg Bimagrumab | Obesity or overweight | 30 mg | 4 | n/r | n/r |
| Placebo + 1.0 mg Semaglutide | Obesity or overweight | 1.0 mg | 4 | n/r | n/r |
| Placebo + 2.4 mg Semaglutide | Obesity or overweight | 2.4 mg | 4 | n/r | n/r |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | Obesity or overweight | 1.0 mg | 4 | n/r | n/r |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | Obesity or overweight | 2.4 mg | 4 | n/r | n/r |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | Obesity or overweight | 1.0 mg | 4 | n/r | n/r |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Obesity or overweight | 2.4 mg | 4 | n/r | n/r |